Review of pyronaridine anti-malarial properties and product characteristics
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Croft, Simon L. | - |
dc.contributor.author | Duparc, Stephan | - |
dc.contributor.author | Arbe-Barnes, Sarah J. | - |
dc.contributor.author | Craft, J. Carl | - |
dc.contributor.author | Shin, Chang-Sik | - |
dc.contributor.author | Fleckenstein, Lawrence | - |
dc.contributor.author | Borghini-Fuhrer, Isabelle | - |
dc.contributor.author | Rim, Han-Jong | - |
dc.date.accessioned | 2021-09-06T16:52:20Z | - |
dc.date.available | 2021-09-06T16:52:20Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2012-08-09 | - |
dc.identifier.issn | 1475-2875 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/107717 | - |
dc.description.abstract | Pyronaridine was synthesized in 1970 at the Institute of Chinese Parasitic Disease and has been used in China for over 30 years for the treatment of malaria. Pyronaridine has high potency against Plasmodium falciparum, including chloroquine-resistant strains. Studies in various animal models have shown pyronaridine to be effective against strains resistant to other anti-malarials, including chloroquine. Resistance to pyronaridine appears to emerge slowly and is further retarded when pyronaridine is used in combination with other anti-malarials, in particular, artesunate. Pyronaridine toxicity is generally less than that of chloroquine, though evidence of embryotoxicity in rodents suggests use with caution in pregnancy. Clinical pharmacokinetic data for pyronaridine indicates an elimination T-1/2 of 13.2 and 9.6 days, respectively, in adults and children with acute uncomplicated falciparum and vivax malaria in artemisinin-combination therapy. Clinical data for mono or combined pyronaridine therapy show excellent antimalarial effects against P. falciparum and studies of combination therapy also show promise against Plasmodium vivax. Pyronaridine has been developed as a fixed dose combination therapy, in a 3: 1 ratio, with artesunate for the treatment of acute uncomplicated P. falciparum malaria and blood stage P. vivax malaria with the name of Pyramax(R) and has received Positive Opinion by European Medicines Agency under the Article 58 procedure. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | BIOMED CENTRAL LTD | - |
dc.subject | UNCOMPLICATED FALCIPARUM-MALARIA | - |
dc.subject | PERFORMANCE LIQUID-CHROMATOGRAPHY | - |
dc.subject | MULTIDRUG-RESISTANT MALARIA | - |
dc.subject | IN-VITRO SUSCEPTIBILITY | - |
dc.subject | MASS SPECTROMETRY ASSAY | - |
dc.subject | BERGHEI ANKA STRAIN | - |
dc.subject | PLASMODIUM-FALCIPARUM | - |
dc.subject | INVITRO ACTIVITY | - |
dc.subject | RODENT MALARIA | - |
dc.subject | DRUG-RESISTANCE | - |
dc.title | Review of pyronaridine anti-malarial properties and product characteristics | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Rim, Han-Jong | - |
dc.identifier.doi | 10.1186/1475-2875-11-270 | - |
dc.identifier.scopusid | 2-s2.0-84864685075 | - |
dc.identifier.wosid | 000310786200001 | - |
dc.identifier.bibliographicCitation | MALARIA JOURNAL, v.11 | - |
dc.relation.isPartOf | MALARIA JOURNAL | - |
dc.citation.title | MALARIA JOURNAL | - |
dc.citation.volume | 11 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Infectious Diseases | - |
dc.relation.journalResearchArea | Parasitology | - |
dc.relation.journalResearchArea | Tropical Medicine | - |
dc.relation.journalWebOfScienceCategory | Infectious Diseases | - |
dc.relation.journalWebOfScienceCategory | Parasitology | - |
dc.relation.journalWebOfScienceCategory | Tropical Medicine | - |
dc.subject.keywordPlus | UNCOMPLICATED FALCIPARUM-MALARIA | - |
dc.subject.keywordPlus | PERFORMANCE LIQUID-CHROMATOGRAPHY | - |
dc.subject.keywordPlus | MULTIDRUG-RESISTANT MALARIA | - |
dc.subject.keywordPlus | IN-VITRO SUSCEPTIBILITY | - |
dc.subject.keywordPlus | MASS SPECTROMETRY ASSAY | - |
dc.subject.keywordPlus | BERGHEI ANKA STRAIN | - |
dc.subject.keywordPlus | PLASMODIUM-FALCIPARUM | - |
dc.subject.keywordPlus | INVITRO ACTIVITY | - |
dc.subject.keywordPlus | RODENT MALARIA | - |
dc.subject.keywordPlus | DRUG-RESISTANCE | - |
dc.subject.keywordAuthor | Pyronaridine | - |
dc.subject.keywordAuthor | Plasmodium falciparum | - |
dc.subject.keywordAuthor | Plasmodium vivax | - |
dc.subject.keywordAuthor | Review | - |
dc.subject.keywordAuthor | Artemisinin containing compound | - |
dc.subject.keywordAuthor | Anti-malarial therapy | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.